Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 15, 2013, Pages

  Snape, Matthew D ^a   Saroey, Praveen ^a   John, Tessa M ^a   Robinson, Hannah ^a   Kelly, Sarah ^a   Gossger, Nicoletta ^a   Yu, Ly Mee ^a   Wang, Huajun ^b   Toneatto, Daniela ^b   Dull, Peter M ^b   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4CMENB VACCINE; ANTIBIOTIC AGENT; BACTERIUM ANTIBODY; BLOOD GROUP B ANTIBODY; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CERVICAL LYMPHADENOPATHY; CHILD; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; MALE; MENINGOCOCCOSIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OTITIS MEDIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REVIEW; SERUM BACTERICIDAL ANTIBODY ASSAY; STRAIN DIFFERENCE; VACCINATION;

EID: 84886398159     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.130257     Document Type: Article

References (19)

1. Summary of opinion: Bexsero. London (UK): European Medicines Agency; 2012. Available: www.ema.europa .eu/docs/en GB/document-library/Summary-of- opinion-Initial authorisation/human/002333/WC500134836.pdf (accessed 2013 May 8).
2. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82.
3. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
4. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010; 29:e71-9.
5. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
6. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35.
7. Summary of product characteristics: Bexsero. London (UK): European Medicines Agency; 2013. Available: www.ema.europa .eu/docs/en-GB/document- library/EPAR-Product Information/human/002333/WC500137881.pdf (accessed 2013 May 8).
8. Ramsay M. Current epidemiology of meningococcal disease in the UK and Europe. London (UK): Meningitis Research Foundation; 2011.
9. Findlow J, Holland A, Andrews N, et al. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay. Clin Vaccine Immunol 2007;14:1451-7.
10. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011;96:744-51.
11. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
12. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7.
13. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7.
14. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-8.
15. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010;107:19490-5.
16. Donnelly J, Medini D, Giuliani MM, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Proceedings of the 11th meeting of the European Meningococcal Disease Society (EMGM); 2011 May 18-20; Ljubljana (Slovenia).
17. Smith H, Nissen M, Sloots T, et al. Estimating the potential strain coverage in Australia of a multicomponent vaccine targeting serogroup B meningococci. Melbourne (Australia): World Society for Pediatric Infectious Diseases; 2011.
18. Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013; Apr. 12 [Epub ahead of print].
19. Hong E, Giuliani MM, Deghmane AE, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 2013;31:1113-6.